Nerve stimulation boosts botulinum toxin action in spasticity

Movement Disorders

Volumn 20, Issue 5, 2005, Pages 624-629

  Frasson, Emma ^a   Priori, Alberto ^b   Ruzzante, Barbara ^a   Didonè, Giuseppe ^a   Bertolasi, Laura ^c  

^a Riva Ospedale   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Dipartimento di Scienze Neurologiche e della Visione   (Italy)

Author keywords

Botulinum toxin A; Electrical nerve stimulation; Muscle activity; Spasticity

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ANKLE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ELECTROMYOGRAPHY; EXTENSOR MUSCLE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MUSCLE ACTION POTENTIAL; MUSCLE CONTRACTION; NEUROMUSCULAR BLOCKING; PERONEUS NERVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; SPASTIC PARESIS; SPASTICITY; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT OUTCOME;

AGED; BOTULINUM TOXIN TYPE A; COMBINED MODALITY THERAPY; ELECTRIC STIMULATION THERAPY; ELECTROMYOGRAPHY; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PARAPARESIS, SPASTIC; PERONEAL NERVE;

EID: 20844448738     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20395     Document Type: Article

References (37)

1. Hughes R, Walker BC. Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by clostridium botulinum toxin type A. J Physiol 1962;160:221-233.
2. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980;212:16-21.
3. Gardiner PF, Michel R, Iadeluca G. Previous exercise training influences functional sprouting of rat hindlimb motoneurones in response to partial denervation. Neurosci Lett 1984;45:123-127.
4. Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographie evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol 1986;103:535-544.
5. Kim HS, Hwang JH, Jeong ST, et al. Effect of muscle activity and betulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol 2003;45:200-206.
6. Eleopra R, Tugnoli V, De Grandis D. The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans. Mov Disord 1997;12:89-94.
7. Chen R, Karp BI, Goldstein SR, Bara-Jimenez W, Yassen Z, Hallett M. Effect of muscle activity immediately after botulinum toxin injection for writer's cramp. Mov Disord 1999;14:307-312.
8. Snow BJ, Tsui JK, Bhatt MH, Hashsmnto SA, Calne DB. Treatment of spasticity with bntulinum toxin: a double-blind study. Ann Neurol 1990;28:512-515.
9. Nemin B, Pollak P, Hommel M, Perrett J. Treatment of spasticity with botulinum toxin. Rev Neurol (Paris) 1992;148:212-214.
10. Pierson SH, Katz DI, TarsyD. Botulinum toxin A in the treatment of spasticity: functional implications and patient selection. Arch Phys Med Rehabil 1996;77:717-721.
11. Hesse S, Reiter F, Konrad M, et al. Botulinum toxin type A and short term electrical stimulation in the treatment of upper-limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin Rehabil 1998;12:381-388.
12. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper limb extremity spasticity: a randomised double blind, placebo-controlled trial. Neurology 1996;46:1306-1310.
13. Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA. Impact of botulinum toxin on disability and earer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217-221.
14. Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of upper leg adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000;68:707-712.
15. Smith SJ, Ellis E, White 5, Moore AP. A double-blind placebo-controlled study of butulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000;14:5-13.
16. Bakheit AM, Pittock S, Moore AP, et al. A randonmised, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke, Eur J Neurol 2001;8:559-565.
17. Pittoek SJ, Moore AP, Hardiman EE, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003;15:289-300.
18. Hesse S, Jahnke MT, Luecke D, et al. Short-term electrical stimulation enhances the effectiveness of botulinum toxin in the treatment of lower-limb splasticity in hemiparetic patient. Neurosci Lett 1995;201:37-40.
19. Hesse S, Brandle-Hesse B, Bardeleben A, Werner C, Funk M. Botulinum toxin type A treatment of adult upper and lower limb splasticity. Drugs Aging 2001;18:255-262.
20. Detrembluer C, Lejeune TM, Renders A, Van Denn Bergh PY. Botumlinum toxin and short-term electrical stimulation in the treament of equinus in celebral palsy. Mov Disord 2002;17:162-169.
21. Lieber RL, Steinman S, Barash IA, Chambers H. Structural and functional changes in spastic skeletal muscle [review]. Muscle Nerve 2002;29:615-627.
22. Sloop RR, Escutin RO, Matus JA, Cole BA, Peterson GW. Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A. Neurology 1996;46:1386-1386.
23. Hamjian JA, Walker FO. Serial nerophysiological studies of intramuscular botulinum-A toxin in humans. Muscle Nerve 1994; 17:1385-1392.
24. Kessler KR. Benecke R. The EDB test - a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 1997;12:95-99.
25. vanPutten MJ, Padberg M, Tavy DL. In vivo analysis of end-plate noise of human extensor digitorum brevis muscle after intramuscular injected botulinum toxin type A. Muscle Nerve 2002;26: 784-790.
26. Buchthal F. Fibrillations: clincal electrophysiology. In: Culp WJ, Ochoa J, editors. Abnormal nerves and muscles as impulse generators. New York: Oxford University Press; 1982. p 632-662.
27. Kimura J. Electrodiagnosis in disease of nerve and muscle: principle and practice. 3rd ed. New York: Oxford University Press, Inc; 2001.
28. Stalberg E, Trontelj JV. Single Fibre electromyography. Surrey, UK: Old Wolking; 1979.
29. Hallett M, Glocker FX, Deuschl G. Mechanism of action of botulinum toxin. Ann Neurol 1994;36:449-450.
30. Glocker FX, Guschlbauer B, Lucking CH, Deuschl G. Effects of local injections of botulinum toxin on electrophysiological parameters in patients with hemifacial spasm: role of synaptic activity and size of motor units. Neurosci Lett 1995;187:161-164.
31. Priori A, Beradelli A, Mercuri B, Manfredi M. Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearms muscles. Brain 1995;118(Pt 3):801-807.
32. Rosales RL, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996;19:488-496.
33. Bertolasi L, Priori A, Tomelleri G, et al. Butulinum toxin treament of muscle cramps: a clinical and neurophysiological study. Ann Neurol 1997;41:181-186.
34. Byrnes ML, Thickbroom GW, Wilson SA, et al. The cortico-motor representation of upper limb muscle in writer's cramp and changes following botulinum toxin injection. Brain 1998;121:977-988.
35. Gilio F, Curra A, Lorenzano C, Modugno N, Manfredi M, Berardelli A. Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann Neurol 2000;48:20-26.
36. Hallett M. How does botulinum toxin work? Ann Neurol 2000;48: 7-8.
37. Seib TP, Price R, Reyes MR, Lenhmanan JF. The quantitative measurement of spasticity: effect of cutaneous electrical stimulation. Arch Phys Med Rehabil 1994;75:746-750.